Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities 1 (Details) - USD ($) $ in Thousands |
Sep. 30, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|---|---|---|---|
| Compensation expense | $ 1,462 | $ 175 | $ 762 |
| Total | 4,505 | 1,424 | 2,601 |
| Pieris Pharmaceuticals, Inc. [Member] | |||
| Compensation expense | 2,306 | 6,448 | 3,015 |
| Research and development fees | 0 | 968 | 5,758 |
| Accrued accounts payable | 60 | 558 | 1,245 |
| Other current liabilities | 1,031 | 363 | 483 |
| Accrued license obligations | 56 | 213 | 245 |
| Total | $ 3,453 | $ 8,550 | $ 10,746 |
| X | ||||||||||
- Definition Amount of current portion of accrued accounts payable. No definition available.
|
| X | ||||||||||
- Definition Amount of current portion of accrued collaboration costs. No definition available.
|
| X | ||||||||||
- Definition Amount of current portion of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of accrued research and development costs. No definition available.
|
| X | ||||||||||
- Definition Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|